Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2011-03-15
2011-03-15
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S278100, C514S003100, C514S012200, C530S300000, C530S308000
Reexamination Certificate
active
07906146
ABSTRACT:
Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5686511 (1997-11-01), Bobo
patent: 5839443 (1998-11-01), Rose et al.
patent: 6051557 (2000-04-01), Drucker
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6376549 (2002-04-01), Fine et al.
patent: 6451974 (2002-09-01), Hansen
patent: 6902744 (2005-06-01), Kolterman et al.
patent: 7902744 (2005-06-01), Kolterman et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 7427663 (2008-09-01), Chen et al.
patent: 2001/0006876 (2001-07-01), Kondo et al.
patent: 2005/0026834 (2005-02-01), Cox et al.
patent: 199731732 (1998-01-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/40788 (1999-08-01), None
patent: WO 00/41546 (2000-07-01), None
patent: WO 00/41548 (2000-07-01), None
Polyols (2010, updated) Mannitol, www.polyol.org/fap/fap—mannitol.html, p. 1-2.
Wikipedia (2010, updated) Sugar alcohol, en.wikipedia.org/wiki/Sugar—alcohol, pp. 1-2.
Bloom, S.R., “Glucagonoma Syndome”; American J. Medical 82(5B):25-36, Review. (1987).
Byrne, M.M., et al ., “Lessons from Human Studies with Glucagon-like Peptide-1: Potential of the Gut Hormone for Clinical Use,” Front. Diabetes, 13:219-33(1997).
Carlsson, A. et al., Insulin and Glucagon Secretion in Patients with Slowly Progressing Autoimmune Diabetes (LADA). J. Clin. Endocrinol. Metab.; 85:76-80(2000).
Chen, Y.E., et al., “Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard,” Journal of Biological Chemistry, 272 (7):4108-4115 (1997).
Creutzfeldt, W.O.C., et al., “Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagonlike Peptide 1(7-36) Amide in Type I Diabetic Patients,” Diabetes Care 19 (6):580-6 (1996).
D'Alessio, et al . , “Elimination of the Action of Glucagonlike Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,” J. Clin. Invest., 97:133-38 (1996).
Daniel, O. et al.,“Use of Glucagon in the Treatment of Acute Diverticultis,” British Medical Journal, 3:720-2, (1974).
Delgado, et al. (1979) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. vol. 9, issues 3-4, pp. 249-304.
Drucker, D. J., “Glucagon-like Peptides” Diabetes, 47:159-169 (1998).
Egan, J.M., et al . , “Glucagon-like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats,” Diabetologia, 40(Supp 1);A130 abstract 505 (1997).
Eissele, et al . , “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide,” Life Sci., 55(8):629-34.
Eng, J., et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,” J. Biol. Chem., 265 (33):20259-62 (1990).
Eng, J., et al.. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,” J. Biol. Chem., 267 (11):7402-05 (1992).
Eng, J., et al., “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice,” Diabetes. 45(Supp 2):152A (abstract 554) (1996).
Francis, et al., “PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques,” International Journal of Hematology, 68 (1):1-18 (1998).
Glauser, et al., “Intravenous Glucagon in the Management of Esophageal Food Obstruction,” JACEP, 8:228-231(1979).
Goke, et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulinsecreting /3-Cells,” J. Biol. Chem., 268 (26):19650-55 (1993).
Holst, J. J. Treatment of type 2 diabetes mellitus with agonists of the Emerg Drugs. vol. 9, No. 1, pp. 155-166. Review.(2004).
Lefebvre, et al, (1979) Glucagon and diabetes: a reappraisal. Diabetologia, vol. 18, No. 6, pp. 347-354.
Malhotra, et al., “Exendin-4, a New Peptide fromHeloderma sospectumVenom, Potentiates Cholecystokinin-Induced Amylase Release from Rat Pancreatic Acini,” Regulatory Peptides, 41:149-56 (1982).
Markletter, Aug. 24, 1998 (page n/a).
O'Halloran, et al, “Glucagon-like Peptide-1 (7-36)-NH2: A Physiologic Inhibitor of Gastric Acid Secretion in Man,” J. Endocrinol. 126 (1) : 169-73 (1990).
Ørskov, et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,” Diabetes, 42:658-61 (1993).
Parhes, D.G. et al, (2001) “Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro” Metabolic, vol. 50, pp. 583-589.
Passa, P., et al , “Mechanisms Suppressing Glucagon Secretion in Glucagonomas,” Diabetologia, 19(3):305 [abstract 298] (1980).
Raufman, et al., “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas,” J. Biol. Chem., 267 (30) :21432-37 (1992).
Schepp, et al., “Exendin-4 and Exendin-(9-3 9)NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,” Eur. J. Pharm., 269:183-91 (1994).
Schjoldager, et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,” Dig. Dis. Sci., 34(5):703-8 (1989).
Singh, et al., “Use of 125I-[Y39] exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig,” Regul. Pep., 53:47-59 (1994).
Stower, et al., “A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease,” Br. J. Surg., 69:591-2(1982).
Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H. “Role of Organic Anion Transporter 1 (OAT1) in Cephaloridine (CER)-Induced Nephrotoxicity.” Kidney Int.;56:2128-2136 (1999).
Thorens, “Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1,” Proc. Natl. Acad. Sci. USA, 89:8641-45 (1992).
Turton, M.D., et al., “A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding,” Nature, 379:69-72 (1996).
Varshavsky A. “The Ubiquitin System.” Trends Biochem Sci. 1997; 22:383-7.
Wettergren, et al. , “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man” Dig. Dis. Sci. , 38(4):665-73 (1993).
Willms, et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mai: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,” J. Clin. Endocrinol. Metab., 81(I):327-32 (1996).
Kolterman Orville G.
L'Italien James J.
Young Andrew A.
Amylin Pharmaceuticals Inc.
Desai Anand U
Liu Samuel
LandOfFree
Lyophilized formulations of exendins and exendin agonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lyophilized formulations of exendins and exendin agonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lyophilized formulations of exendins and exendin agonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2766558